Linagliptina Mylan (Linagliptin)

Linagliptin works by reversibly inhibiting the enzyme dipeptidyl peptidase‑4 (DPP‑4). This inhibition prevents the breakdown of the incretin hormones GLP‑1 and GIP, which increases their levels in the bloodstream. Higher incretin levels enhance glucose‑dependent insulin secretion and suppress glucagon release, resulting in improved glycemic control.

The specific dose of Linagliptina Mylan is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal and hepatic function, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

The safety of linagliptin in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternative treatment options with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements), and assist with import documentation.

Linagliptin is unique among DPP‑4 inhibitors because it is primarily eliminated via the entero‑hepatic route and does not require dose adjustment in renal impairment, unlike many of its peers. Efficacy in lowering HbA1c is comparable to other agents in the class, while its safety profile is similar, with low risk of hypoglycemia when used as monotherapy.

Linagliptina Mylan should be stored at ambient temperature, below 25 °C (77 °F). Keep the tablets in the original blister pack or container, protect them from moisture, heat, and direct sunlight. Do not store in the bathroom or near a kitchen sink. Ensure the product is kept out of reach of children.

Linagliptina Mylan is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare professional and should not split, crush, or chew the tablet unless specifically instructed.

The most serious risks include pancreatitis, severe hypersensitivity reactions such as anaphylaxis or angioedema, and rare cases of hepatic injury. Patients should be educated to seek immediate medical attention if they experience persistent abdominal pain, signs of an allergic reaction, or unexplained jaundice while on therapy.

Linagliptina Mylan is contraindicated in patients with a known hypersensitivity to linagliptin or any of the tablet’s excipients. It should be used with caution in individuals with a history of pancreatitis, severe hepatic impairment, or uncontrolled heart failure. Pregnant or breastfeeding women should only use it if clearly indicated by a physician.